Boston Scientific Corporation found using ticker (BSX) have now 26 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 59 and 45 with a mean TP of 53. Given that the stocks previous close was at 47.18 this indicates there is a potential upside of 12.3%. The day 50 moving average is 46.5 and the 200 day moving average is 42.05. The market cap for the company is $67,449m. Visit the company website at: https://www.bostonscientific.com
The potential market cap would be $75,769m based on the market concensus.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.